China News Agency, Beijing, February 11 (Reporter Li Chun) talked about whether the centralized procurement of drugs and high-value medical consumables will affect the production enthusiasm of pharmaceutical companies. The briefing stated that China is fully promoting the construction of a healthy China, and drug use will be a rigid need. "The profit point of enterprises is here, and it is impossible for no one to do it."
According to media reports, there is a high degree of public acceptance for the centralized procurement of medicines and high-value medical consumables, but some pharmaceutical companies are more anxious.
Some voices pointed out that this reform may affect the innovation and production enthusiasm of pharmaceutical companies.
Chen Jinfu said that the promotion of the centralized procurement system, including the setting of specific operating rules, always puts the three goals of the healthy development of the pharmaceutical industry, the improvement of clinical quality, and the accessibility of medical treatment to the common people, and the overall consideration is balanced.
From the very beginning of its design, this system has been focusing on the problem of inflated drug prices, focusing on providing high-quality drugs for the Chinese people, using price tools, and playing the role of market mechanisms.
He pointed out that "purchasing with quantity and integrating recruitment and procurement" is for the consideration of enterprises, which can enable enterprises to go from private hospitals to face-to-face quality competition and price competition, so as to further expand and strengthen large-scale industries and leading enterprises.
"Only through the competition mechanism of volume-based procurement and recruitment can enterprises be able to compete under real market conditions. This is an institutional arrangement."
Chen Jinfu also said that China is promoting the construction of a healthy China in an all-round way, and the medical level of the people will be greatly improved in the process of development, so medication will be a rigid need.
"Some people worry that no one will provide medicines after the price comes down. In fact, the immediate needs are here, the development is here, and the profit point of the company is here. It is impossible for no one to do it."
According to the briefing, since the launch of centralized procurement with volume, the R&D expenses of some pharmaceutical companies, especially leading companies, have gradually increased, and the R&D expenses of some companies have risen from the original 6% and 10% to 20%.
Chen Jinfu believes that this means that leading companies in the pharmaceutical industry can not only make generic drugs, but also need to develop innovative products and core technologies.
He pointed out that institutional promotion can enable Chinese pharmaceutical companies to maintain quality and drive innovation through fair competition, which must rely on market mechanisms.
It is naturally good and bad for enterprises: using market rules to achieve effective cost control and optimization and quality innovation will occupy the future market; there are also some enterprises that cannot adapt to this reform and may survive the fittest. More efficient use of resources.
"In the past, on the one hand, the quality level of the pharmaceutical industry could not be improved, and on the other hand, it was sold in large quantities, and 'magic medicine' was flying all over the sky. "Chen Jinfu believes that the impact of centralized procurement with volume is institutional, and it is also an important basic leverage to promote the high-quality development of the pharmaceutical industry.
(Finish)